Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Press Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi ends development of Clostridium difficile vaccine
Paris, France - December 1, 2017 - Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has therefore decided to discontinue clinical development of its experimental Clostridium difficile vaccine, to focus on six key vaccine projects currently in development.
Cdiffense is a trial designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of Clostridium difficile infection.
Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program. Data from all vaccinated volunteers in this trial will continue to be analyzed for more information and shared with the scientific community.
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | |
| Media Relations Contact Laurence Bollack Tel. : +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/71a34018-8251-439a-a1b1-6fd9d33d93b2
